Aglaris Secures Major Funding to Drive Commercialisation of Ground- breaking Cell-based Therapy Manufacturing System




LONDON - 27 March 2019

Aglaris Ltd, the innovator in cell therapy manufacturing, has been awarded three prestigious grants totalling over €2million to advance its breakthrough technologies towards commercialisation.

The grants have been awarded by the EU's H2020 and Eurostart programmes and by Innovate-UK.

Aglaris will execute the development projects in collaboration with partners such as Histocell, the Cell and Gene Therapy Catapult, Sartorius Stedim Biotech and UCL.

The programmes will be focused on final development of the Aglaris "Facer" system for the robust, autonomous production of high numbers of quality cells for therapeutic use, on optimising the production of T cell and MSC-based therapeutics and on a new range of microcarriers for adherent cell culture.

Steve Docksey, CEO of Aglaris, said "We are very proud to have been awarded these grants from such highly regarded programmes and to be working with several excellent partners in the field of cell therapy. We will be bringing much-needed innovation and performance to the manufacturing of these exciting new therapeutics."

*** END ***

About Aglaris Ltd

Aglaris is creating transformative technologies to address key challenges in cell-based therapy bioprocessing. The company’s platform cell expansion technology, the Facer system, aims to bring quality, consistency, scalability and productivity to the manufacturing of cell-based therapeutics by enabling the robust GMP / CMC disciplines that are the bedrock of the pharmaceutical industry. Aglaris's head office and main R&D facilities are located at the Stevenage Bioscience Catalyst between London and Cambridge with additional specialist laboratories at the Tres Cantos Science Park in Madrid, Spain.

RSS de esta página